Harpoon Therapeutics, Inc.
NASDAQ: HARP0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Julie M. Eastland
- Employees
- 45
- Headquarters
- South San Francisco, United States
- IPO year
- 2019
- Market cap
- $865.1M
- Website
- https://www.harpoontx.com
Loading HARP…
Loading profile data…Frequently asked questions about HARP
What does Harpoon Therapeutics, Inc. (HARP) do?
Harpoon Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to immunotherapy, focused on engineering a novel class of T cell activators. These therapies are designed to leverage the body's own immune system to fight cancer and other diseases in patients across the United States. The company's innovative Tri-specific T cell activa...
Where does HARP trade?
Harpoon Therapeutics, Inc. (HARP) trades on the NASDAQ Global Select.
What sector is HARP in?
Harpoon Therapeutics, Inc. (HARP) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Harpoon Therapeutics, Inc.?
Julie M. Eastland is the chief executive officer of Harpoon Therapeutics, Inc. (HARP).
Where is Harpoon Therapeutics, Inc. headquartered?
Harpoon Therapeutics, Inc. is headquartered in United States.
Does HARP pay a dividend?
Harpoon Therapeutics, Inc. (HARP) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did HARP go public?
Harpoon Therapeutics, Inc. (HARP) completed its initial public offering in 2019.